SM04690

DRUG4 trials

Sponsors

Biosplice Therapeutics, Inc.

Conditions

Degenerative Disc DiseaseKnee OsteoarthritisOsteoarthritis

Phase 1

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

TerminatedNCT03246399

Biosplice Therapeutics, Inc.Degenerative Disc Disease

Start: 2017-07-26End: 2018-12-04Updated: 2019-04-23

Phase 2

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

CompletedNCT02536833

Biosplice Therapeutics, Inc.Osteoarthritis

Start: 2015-09-09End: 2017-04-20Updated: 2021-03-17

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

CompletedNCT03122860

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2017-04-24End: 2018-04-30Updated: 2021-06-11

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

CompletedNCT03727022

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2018-11-28End: 2021-08-18Updated: 2026-01-12

Related Papers

Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials.

2025-05-016 citations

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

Rheumatology and Therapy2025-01-043 citations

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.

2023-10-302 citations

Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint

The American Journal of Sports Medicine2022-01-1017 citations

Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.

2021-06-0813 citations

Wnt signaling: a promising target for osteoarthritis therapy.

2019-08-16146 citations

EULAR 2017: Annual European Congress of Rheumatology, June 14–17, 2017, Madrid, Spain

EBioMedicine2017-08-142 citations